Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced or Metastatic ER+ Breast Cancer 1

Interventions

Cisplatin 3205Cyclophosphamide 3200Carboplatin 2979Radiotherapy 2790Paclitaxel 2720Gemcitabine 2573pembrolizumab 2388Bevacizumab 2210Docetaxel 2200Fluorouracil 1851Capecitabine 1834Oxaliplatin 1742Dexamethasone 1606Nivolumab 1581Doxorubicin 1503Rituximab 1489Magnetic Resonance Spectroscopy 1391Etoposide 1346Irinotecan 1248Leucovorin 1227Drug Therapy 1205Cytarabine 1131Pemetrexed 1078fludarabine 1065Specimen Handling 1021Vincristine 966Trastuzumab 946Cetuximab 945Prednisone 943Lenalidomide 938

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
LSZ102 × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡